Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$15.13 USD

15.13
7,421,396

-0.21 (-1.37%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $15.12 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Crinetics Pharmaceuticals (CRNX) Stock Jumps 19.1%: Will It Continue to Soar?

Crinetics Pharmaceuticals (CRNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

Catalyst (CPRX) reports encouraging fourth-quarter results, driven by Firdapse and Fycompa sales. The stock gains in the pre-market session.

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks.com featured highlights include GigaCloud Technology, SkyWest, Ramaco Resources, Eastman Chemical and Catalyst Pharmaceuticals

GigaCloud Technology, SkyWest, Ramaco Resources, Eastman Chemical and Catalyst Pharmaceuticals are part of the Screen of the Week article.

Best Momentum Stocks to Buy for January 10th

IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.

Rimmi Singhi headshot

5 Value Stocks With Strong Earnings Yield to Rev Up Returns

Consider investing in high-yield value stocks like GCT, SKYW, METC, EMN and CPRX to unlock your portfolio's potential.

New Strong Buy Stocks for January 10th

PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Catalyst (CPRX) is an Incredible Growth Stock: 3 Reasons Why

Catalyst (CPRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?

Catalyst Pharmaceuticals (CPRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up

Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales continue to boost revenues. Management raises 2023 financial guidance. The stock gains 6% in the after-market hours.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst's (CPRX) third-quarter 2023 earnings are expected to have been driven by the robust performances of its two marketed drugs, Firdapse and Fycompa CIII.

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.